comparision of rivaroxaban with enoxaparin in fractures

Efficacy of Rivaroxaban versus Enoxaparin for thromboprophylaxis in patients with lower limb fractures

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190305042931N1

Enrollment

242

Registered

2019-11-25

Start date

2019-05-22

Completion date

Unknown

Last updated

2019-12-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thromboembolic events. Pulmonary embolism

Interventions

Intervention 1: Intervention group: Patients 18 to 70 years old with lower extremity fractures receiving rivaroxaban oral prophylaxis for thromboembolic events. Intervention 2: Control group: Patients

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: All individuals aged 18 to 70 years with major lower limb fractures undergoing skeletal fixation surgery will be included in this study.

Exclusion criteria

Exclusion criteria: History of thromboembolic events History of major hemorrhages without cause Women who take OCP Several fractures in the lower extremities or simultaneous fractures in the upper extremity consciousness level disturbance Joint patient with other surgical services

Design outcomes

Primary

Measure	Time frame
Incidence of thromboembolic events in patient. Timepoint: Up to 3 months after trauma. Method of measurement: Lower limbs Color Doppler Ultrasound.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMahmoud Najafi

Arak University of Medical Sciences

mahmoudnajafi20@gmail.com+98 86 3406 1555

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026